About: Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
Creator	Ho, Tin-Yun Hsiang, Chien-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping
Source	Elsevier; Medline; PMC
abstract	Abstract Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-β-d-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2–0.3mg/100ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy.
has issue date	2004-01-23(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2003.11.180
bibo:pmid	14706633
has license	els-covid
sha1sum (hex)	44bbdaa4c3b3f4c165fd80716537cf94791052ef
schema:url	https://doi.org/10.1016/j.bbrc.2003.11.180
resource representing a document's title	Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
has PubMed Central identifier	PMC7111049
has PubMed identifier	14706633
schema:publication	Biochemical and Biophysical Research Communications
resource representing a document's body	covid:44bbdaa4c3b3f4c165fd80716537cf94791052ef#body_text
is schema:about of	named entity 'RECEPTOR' named entity 'ABILITY' named entity 'MIGHT BE' named entity '0.3' named entity 'NICKEL' named entity 'PROTEIN ' named entity 'WORLDWIDE' named entity 'RECOVERED' named entity 'ORDER' named entity 'ITS' named entity 'RESPONSIBLE' named entity 'A MAJOR' named entity 'SPIKE' named entity 'USING' named entity 'CAUSING' named entity 'BINDING' named entity 'ANTIGENICITY' named entity 'STRUCTURAL PROTEINS' named entity '0.2' named entity 'ELISA' named entity 'CANDIDATE' named entity 'WESTERN BLOT' named entity 'S PROTEIN' named entity 'CELLULAR' named entity 'SPECIFIC' named entity 'IS A' named entity 'NEUTRALIZING ANTIBODY' named entity 'RETAINED' named entity 'RECOMBINANT' named entity 'SARS CORONAVIRUS' named entity 'DEVELOPING' named entity 'CONTAINS' named entity 'OUTBREAKS' named entity 'SERA' named entity 'TAKEN' named entity '130' named entity 'NOVEL CORONAVIRUS' named entity 'IDENTIFIED' named entity 'ASSOCIATED WITH' named entity 'EMERGING INFECTIOUS DISEASE' named entity 'PET' named entity '28S' named entity 'SOLUBLE FORM' named entity 'ABILITY' named entity 'BACTERIAL CULTURE' named entity 'PROBE' named entity 'INDICATED' named entity 'RECOMBINANT' named entity 'SPIKE PROTEIN' named entity 'SARS CORONAVIRUS' named entity 'THESE' named entity 'ISOPROPYL' named entity 'KDA' named entity 'GOOD' named entity 'AFFINITY CHROMATOGRAPHY' named entity '140' named entity 'ESCHERICHIA COLI' named entity 'EXPRESSED' named entity 'SARS VACCINE' named entity 'INDUCTION' named entity 'ANTIGENICITY' named entity 'D D' named entity 'DISEASE ASSOCIATED' named entity 'VERO CELLS' named entity 'RNA VIRUS' named entity 'ANTIGENIC DETERMINANT' named entity 'HOMOGENEITY' named entity 'RECEPTORS' named entity 'PATIENTS' named entity 'BINDING' named entity 'EXPRESSION VECTOR' named entity 'PROTEINS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'RECEPTOR' named entity 'SARS' named entity 'MG%'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software